Mark Zuckerberg and wife Dr. Priscilla Chan recently announced a $3 billion initiative geared towards curing most of the world’s diseases called the Biohub. Through the Chan Zuckerberg Initiative, the couple managed to draw support from other billionaires and ordinary people alike in terms of funding and cooperation. Recently, the Facebook founder released a post detailing how a meeting with top scientists gave him hope that most, if not all of the world’s diseases will be gone by 2115.
The scientists in question are at the top of their fields with regards to dealing with illnesses and they come from multiple origins, including Stanford University and UC Berkeley. Heading the team is Dr. Cori Bargmann, who is a Rockefeller neuroscientist, Futurism reports.
Even with excellent brains behind the operation, the goal of eradicating even just a majority of the known diseases plaguing the world is a monumental undertaking. Much of the challenges has to do with research, which is a costly and time-consuming affair. The Biohub will take on a lot of the weight of the problems that usually prevent scientists from making swift progress, but even then, many would consider the 100-year timeline to be overly ambitious.
Zuckerberg and the team of scientists don’t seem to think so, however, and they point to the advancements that humanity has achieved in the last few decades in extending human lifespan. Global Futurist also notes how the initiative has already addressed one of the hurdles of getting to the point that they are aiming for; coordination.
There’s also the matter of the most recent innovations in medical and bioresearch to consider, which gives the lofty goals of a disease-free world a boost. There’s the new gene-editing tool called CRISPR, which is basically a starter kit for playing God. Then there’s the project called Cell Atlas, which aims to map all of the human body’s cells to address diseases that begin at the cellular level.


Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 



